Latest News

Oslo, 27 April 2017: Photocure ASA (OSE: PHO), held its annual general meeting on 27 April 2017 at 17:00 hours (CET).

Data on US Registry Study for BLC™ with Cysview/Hexvix will also be Presented at AUA.

Oslo, 6 April 2017: Photocure ASA (OSE: PHO), calls for the annual general meeting of PHO to be held at Hoffsveien 4, 1st floor, 0275 Oslo, Norway on 27 April 2017 at 17:00 hours (CET).

• Following non-conclusive partnering discussions, the company will assess further strategic alternatives for Cevira and Visonac • Company still to focus on urology franchise, with continued commitment to driving growth in United States

Oslo, Norway, March 29, 2017, Photocure ASA (OSE: PHO), is pleased to announce that Blue Light Cystoscopy (BLC™) with Hexvix® was featured during the European Association of Urology (EAU) annual meeting held in London, UK, March 24th - 28th. The EAU is one of the largest international meetings in urology, attended by more than 12,000 urologists from over 110 countries.

Oslo, Norway, 15 February 2017: Photocure ASA (OSE: PHO), a specialty pharmaceutical company focused on photodynamic technologies in cancer and dermatology, reported a revenue growth of 10 % to NOK 38.1 million in the fourth quarter of 2016 (Q4 2015: NOK 34.5), with an EBITDA of NOK 10.7 million for the Hexvix/Cysview commercial franchise. Full year 2016 revenues ended at NOK 143.6 million (134.7). Photocure targets revenues from the US operations to quadruple to a range of USD 15 million by 2020.

Oslo, Norway, February 8th 2017, Photocure ASA announced today a publication in the Scandinavian Journal of Urology, describing a vision for improving outcomes for patients with non-muscle-invasive bladder cancer (NMIBC), and the significant role that blue light cystoscopy (BLC) with Hexvix® plays in achieving it.

Photocure will present its fourth quarter and full year 2016 report on Wednesday 15 February 2017 at Hotel Continental, Oslo, Norway.

Oslo, Norway, February 3, 2017 Photocure ASA (OSE: PHO), announced today that it has completed enrollment in its Phase 3 study with BLFC with Cysview in patients with Non Muscle Invasive Bladder cancer (NMIBC) undergoing follow up (surveillance) cystoscopy in the outpatient setting. The enrollment of 300 bladder cancer patients has secured that a minimum of 100 patients have been referred to and received repeat administrations of Blue Light Cystoscopy with Cysview in the operating room setting. In the study, Cysview was used in conjunction with the flexible KARL STORZ system. Results from the study are expected to be available mid-2017.

Blue Light equipment supplier and Photocure partner KARL STORZ Endoscopy-America, Inc. announced its system for performing Blue Light Cystoscopy with Cysview® (BLCC) has received an Innovative Technology designation from Vizient, Inc.

Photocure ASA (OSE: PHO) management is this week conducting investor meetings in San Francisco (US) in connection with the J.P. Morgan healthcare conference.

Oslo, Norway, December 5, 2016 Photocure ASA (PHO-NO) announced today new data from a prospective multicenter real world study that included 338 patients, 415 BLC procedures and 1060 lesions from nine study sites in the United States. BLCC as an adjunct to white light cystoscopy (WLC) resulted in the detection of an additional 151 lesions and 45 patients uniquely with the addition of blue light. This resulted in upgrading or upstaging of 52 (15%) of the patients. Correct staging and grading impacts the management of bladder cancer patients and may have an impact on patient outcomes.

Oslo, Norway, November 28th, 2016 Photocure ASA announced the publication of The Comparative effectiveness of fluorescence cystoscopy versus white light cystoscopy (WLC) for initial diagnosis or surveillance of bladder cancer on clinical outcomes: Systematic review and meta-analysis in the Journal of Urology. This review, which was sponsored by the US Agency for Healthcare Research (AHRQ), concluded that Blue Light Cystoscopy with Cysview®/Hexvix® was associated with decreased risk of progression and recurrence of non-muscle invasive bladder cancer versus White Light Cystoscopy alone.

Update on management shareholdings and exercise of employee share options in Photocure ASA ("the Company").

Edison Group, an investment intelligence firm, has published a company research report on Photocure Q3 2016 results.

Oslo, Norway, 15 November 2016: Photocure ASA (OSE: PHO), a specialty pharmaceutical company focused on photodynamic technologies in cancer and dermatology, reported a revenue growth of 17 % to NOK 31.6 million in the third quarter of 2016 (Q3 2015: NOK 27.0) for the Hexvix/Cysview commercial franchise and a corresponding EBITDA of NOK 8.0 million.